1. participation in other investigational clinical trials for the treatment or prevention of sars-cov-2 infection within 30days 2. unwilling to practice acceptable methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) during screening, while taking study drug, and for at least 30 days after the last dose of study drug is ingested note: the following criteria follow standard clinical practice for fda approved indications of this medication 3. having a prior history of blood disorders such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia 4. having a prior history of glucose-6-phosphate dehydrogenase (g-6-pd) deficiency 5. having dermatitis, psoriasis or porphyria 6. taking digoxin, mefloquine, methotrexate, cyclosporine, praziquantel, antacids and kaolin, cimetidine, ampicillin, insulin or antidiabetic drugs, arrhythmogenic drugs, antiepileptic drugs, loop, thiazide, and related diuretics, laxatives and enemas, amphotericin b, high dose corticosteroids, and proton pump inhibitors, neostigmine, praziquantel, pyridostigmine, tamoxifen citrate 7. allergies: 4-aminoquinolines 8. pre-existing retinopathy of the eye 9. has a chronic liver disease or cirrhosis, including hepatitis b and/or untreated hepatitis 10. untreated or uncontrolled active bacterial, fungal infection 11. known or suspected active drug or alcohol abuse, per investigator judgment 12. women who are pregnant or breastfeeding 13. known hypersensitivity to any component of the study drug 14. a known history of prolonged qt syndrome or history of additional risk factors for torsades de pointe (e.g., heart failure, requires a lab test , family history of long qt syndrome), or the use of concomitant medications that prolong the qt/qtc interval

1. participation in other investigational clinical trials for the treatment or prevention of sars-cov-2 infection within 30days 2. unwilling to practice acceptable methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) during screening, while taking study drug, and for at least 30 days after the last dose of study drug is ingested note: the following criteria follow standard clinical practice for fda approved indications of this medication 3. having a prior history of blood disorders such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia 4. having a prior history of glucose-6-phosphate dehydrogenase (g-6-pd) deficiency 5. having dermatitis, psoriasis or porphyria 6. taking digoxin, mefloquine, methotrexate, cyclosporine, praziquantel, antacids and kaolin, cimetidine, ampicillin, insulin or antidiabetic drugs, arrhythmogenic drugs, antiepileptic drugs, loop, thiazide, and related diuretics, laxatives and enemas, amphotericin b, high dose corticosteroids, and proton pump inhibitors, neostigmine, praziquantel, pyridostigmine, tamoxifen citrate 7. allergies: 4-aminoquinolines 8. pre-existing retinopathy of the eye 9. has a chronic liver disease or cirrhosis, including hepatitis b and/or untreated hepatitis 10. untreated or uncontrolled active bacterial, fungal infection 11. known or suspected active drug or alcohol abuse, per investigator judgment 12. women who are pregnant or breastfeeding 13. known hypersensitivity to any component of the study drug 14. a known history of prolonged qt syndrome or history of additional risk factors for torsades de pointe (e.g., heart failure, requires a lab test , family history of long qt syndrome), or the use of concomitant medications that prolong the qt/qtc interval

participation in other investigational clinical trials for the treatment or prevention of sars-cov-2 infection within 30days unwilling to practice acceptable methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) during screening, while taking study drug, and for at least 30 days after the last dose of study drug is ingested note: the following criteria follow standard clinical practice for fda approved indications of this medication having a prior history of blood disorders such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia having a prior history of glucose-6-phosphate dehydrogenase (g-6-pd) deficiency having dermatitis, psoriasis or porphyria taking digoxin, mefloquine, methotrexate, cyclosporine, praziquantel, antacids and kaolin, cimetidine, ampicillin, insulin or antidiabetic drugs, arrhythmogenic drugs, antiepileptic drugs, loop, thiazide, and related diuretics, laxatives and enemas, amphotericin b, high dose corticosteroids, and proton pump inhibitors, neostigmine, praziquantel, pyridostigmine, tamoxifen citrate allergies: 4-aminoquinolines pre-existing retinopathy of the eye has a chronic liver disease or cirrhosis, including hepatitis b and/or untreated hepatitis untreated or uncontrolled active bacterial, fungal infection known or suspected active drug or alcohol abuse, per investigator judgment women who are pregnant or breastfeeding known hypersensitivity to any component of the study drug a known history of prolonged qt syndrome or history of additional risk factors for torsades de pointe (e.g., heart failure, requires a lab test , family history of long qt syndrome), or the use of concomitant medications that prolong the qt/qtc interval

participation in other investigational clinical trials for the treatment or prevention of sars-cov-2 infection within 30days unwilling to practice acceptable methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) during screening, while taking study drug, and for at least 30 days after the last dose of study drug is ingested note: the following criteria follow standard clinical practice for fda approved indications of this medication having a prior history of blood disorders such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia having a prior history of glucose-6-phosphate dehydrogenase (g-6-pd) deficiency having dermatitis, psoriasis or porphyria taking digoxin, mefloquine, methotrexate, cyclosporine, praziquantel, antacids and kaolin, cimetidine, ampicillin, insulin or antidiabetic drugs, arrhythmogenic drugs, antiepileptic drugs, loop, thiazide, and related diuretics, laxatives and enemas, amphotericin b, high dose corticosteroids, and proton pump inhibitors, neostigmine, praziquantel, pyridostigmine, tamoxifen citrate allergies: 4-aminoquinolines pre-existing retinopathy of the eye has a chronic liver disease or cirrhosis, including hepatitis b and/or untreated hepatitis untreated or uncontrolled active bacterial, fungal infection known or suspected active drug or alcohol abuse, per investigator judgment women who are pregnant or breastfeeding known hypersensitivity to any component of the study drug a known history of prolonged qt syndrome or history of additional risk factors for torsades de pointe (e.g., heart failure, requires a lab test , family history of long qt syndrome), or the use of concomitant medications that prolong the qt/qtc interval

1. participation in other investigational clinical trials for the treatment or prevention of sars-cov-2 infection within 30days 2. unwilling to practice acceptable methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) during screening, while taking study drug, and for at least 30 days after the last dose of study drug is ingested note: the following criteria follow standard clinical practice for fda approved indications of this medication 3. having a prior history of blood disorders such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia 4. having a prior history of glucose-6-phosphate dehydrogenase (g-6-pd) deficiency 5. having dermatitis, psoriasis or porphyria 6. taking digoxin, mefloquine, methotrexate, cyclosporine, praziquantel, antacids and kaolin, cimetidine, ampicillin, insulin or antidiabetic drugs, arrhythmogenic drugs, antiepileptic drugs, loop, thiazide, and related diuretics, laxatives and enemas, amphotericin b, high dose corticosteroids, and proton pump inhibitors, neostigmine, praziquantel, pyridostigmine, tamoxifen citrate 7. allergies: 4-aminoquinolines 8. pre-existing retinopathy of the eye 9. has a chronic liver disease or cirrhosis, including hepatitis b and/or untreated hepatitis 10. untreated or uncontrolled active bacterial, fungal infection 11. known or suspected active drug or alcohol abuse, per investigator judgment 12. women who are pregnant or breastfeeding 13. known hypersensitivity to any component of the study drug 14. a known history of prolonged qt syndrome or history of additional risk factors for torsades de pointe (e.g., heart failure, requires a lab test , family history of long qt syndrome), or the use of concomitant medications that prolong the qt/qtc interval

1. participation in other investigational clinical trials for the treatment or prevention of sars-cov-2 infection within 30days 2. unwilling to practice acceptable methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) during screening, while taking study drug, and for at least 30 days after the last dose of study drug is ingested note: the following criteria follow standard clinical practice for fda approved indications of this medication 3. having a prior history of blood disorders such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia 4. having a prior history of glucose-6-phosphate dehydrogenase (g-6-pd) deficiency 5. having dermatitis, psoriasis or porphyria 6. taking digoxin, mefloquine, methotrexate, cyclosporine, praziquantel, antacids and kaolin, cimetidine, ampicillin, insulin or antidiabetic drugs, arrhythmogenic drugs, antiepileptic drugs, loop, thiazide, and related diuretics, laxatives and enemas, amphotericin b, high dose corticosteroids, and proton pump inhibitors, neostigmine, praziquantel, pyridostigmine, tamoxifen citrate 7. allergies: 4-aminoquinolines 8. pre-existing retinopathy of the eye 9. has a chronic liver disease or cirrhosis, including hepatitis b and/or untreated hepatitis 10. untreated or uncontrolled active bacterial, fungal infection 11. known or suspected active drug or alcohol abuse, per investigator judgment 12. women who are pregnant or breastfeeding 13. known hypersensitivity to any component of the study drug 14. a known history of prolonged qt syndrome or history of additional risk factors for torsades de pointe (e.g., heart failure, requires a lab test , family history of long qt syndrome), or the use of concomitant medications that prolong the qt/qtc interval